Altimmune, Inc. — Form 8-K

Altimmune announced positive topline results from RECLAIM Phase 2 trial of pemvidutide (2.4 mg) in alcohol use disorder (AUD). The trial met its primary endpoint with statistically significant reduction in heavy drinking days versus placebo (p=0.0014; -1.45 days/week difference). Key secondary endpoints also achieved: 64.4% achieved 2-level WHO risk drinking reduction (vs 34.8% placebo, p=0.0049), 42.2% achieved zero heavy drinking days (vs 17.4%, p=0.0066), 9.1% placebo-adjusted weight reduction (p<0.0001). Safety profile generally favorable though nausea (44% vs 24%), constipation (26% vs 6%), and vomiting (18% vs 6%) were elevated; 5 treatment discontinuations due to drug-related AEs (10% vs 0%). Company plans End-of-Phase 2 FDA meeting based on results.